- Home
- MIST vs NVX Comparison
MIST vs NVX Comparison
Compare MIST & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | NVX |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | Canada | Australia |
| Employees | N/A | 202 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.3M | 191.3M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MIST | NVX |
|---|---|---|
| Price | $1.59 | $0.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 577.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3,904.19 |
| Revenue Next Year | N/A | $91.72 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $0.81 |
| 52 Week High | $3.06 | $3.86 |
Technical Indicators
Market Signals| Indicator | MIST | NVX |
|---|---|---|
| Relative Strength Index (RSI) | 30.96 | 38.58 |
| Support Level | $1.38 | $0.83 |
| Resistance Level | $1.79 | $1.02 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 10.55 | 8.51 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.